In a randomized, double-blind clinical trial conducted at 13 medical centers, meropenem (1,000 mg given iv every 8 hours) was compared with the combination of clindamycin (900 mg every 8 hours) plus tobramycin (5 mg/[kg • d] in three divided doses) given iv for the treatment of intraabdominal infections that required surgery and parenteral antibiotic therapy. At the end of treatment, efficacy data on patients who met study inclusion criteria (intent-to-treat) were available for 132 of 215 patients in the meropenem group and 134 of 212 patients in the clindamycin/tobramycin group; 120 (91%) of 132 intent-to-treat patients in the meropenem group were cured, 115 (86%) of 134 intent-to-treat patients in the clindamycin/tobramycin group were cured (P value, not significant). Of the patients treated with meropenem and considered evaluable according to the study protocol, 89 (92%) of 97 were cured, and 81 (86%) of 94 patients treated with clindamycin/tobramycin and considered evaluable were cured. Bacteriologic response rates for all evaluable patients (n = 191) were 96% (93 of 97 patients) among those randomized to the meropenem arm and 93% (87 of 94) among those randomized to the clindamycin/tobramycin arm. Adverse events occurred with similar frequency in both treatment groups; neither seizures nor deaths related to treatment were reported for any patients in either group. The results of this trial demonstrated that meropenem, together with appropriate surgical intervention, was safe and effective in the treatment of patients who had bacterial intra-abdominal infections, most of which were secondary to complicated appendicitis.
A multicenter trial was designed to compare meropenem with a standard aminoglycoside regimen for treating anaerobic intra-abdominal infection. In this study, meropenem (1,000 mg given iv every 8 hours) was compared with a combination regimen of clindamycin (900 mg) and tobramycin mg/[kg • d]) given iv every 8 hours to determine meropenem's safety and efficacy in the treatment of intra-abdominal infections requiring surgery and parenteral antibiotic therapy. Several aspects of this trial have been previously reported [10, 11] . The data on all patients with intra-abdominal infections entered in the North American portion of the trial are reported herein.
Methods
This prospective, multicenter, double-blind, randomized, parallel-group trial was conducted at 13 sites in North America. Patients with a clinical diagnosis of intra-abdominal infection were assigned to receive parenteral treatment with either meropenem or the combination of clindamycin/tobramycin. Trial monitors, trial-site investigators, and their staffs were blinded to the treatments.
Criteria for enrollment. Adult patients (age, years) who had been hospitalized with clinical evidence of intraabdominal infection requiring surgical intervention were eligible for enrollment. Women of childbearing age who were taking oral contraceptives or who agreed to abstain from sexual intercourse during the trial were eligible for inclusion, but pregnant or lactating women were excluded. Other criteria for exclusion are listed in table 1 .
Clinical evidence of intra-abdominal infection included the presence of typical signs and/or symptoms, including a temper- Table 1 . Criteria for exclusion of patients from a randomized, multicenter trial of meropenem vs. clindamycin/tobramycin for treatment of intra-abdominal infections.
• I. Some patients received concomitant therapy with nystatin or vancomycin.
ature of _-38°C, abdominal pain and tenderness, abdominalwall guarding, and leukocytosis. Confirmatory laboratory or radiographic findings were sought when appropriate, as was presumptive evidence of bacterial involvement that was subsequently confirmed by a positive culture of purulent peritoneal fluid. Patients with suspected complicated appendicitis (i.e., the presence of abscess, gangrene, perforation, and/or peritonitis) could be enrolled if they had had a temperature of a'38°C for 24 hours plus a WBC count of >13,000/mm3 . Specific diagnostic categories eligible for inclusion were complicated appendicitis (appendicitis complicated by perforation and regional or general peritonitis with purulent fluid, appendiceal abscess, and/or bacteremia), gynecologic infection, hepatobiliary infection, pancreatic infection, intra-abdominal abscess, and perforation of the stomach or bowel.
Patients with intra-abdominal infections who had been unsuccessfully treated with other antibiotics could be enrolled if the previous antimicrobial therapy had been discontinued before cultures were performed for the present study. Of the 427 patients enrolled, 60 (30 in the meropenem group and 30 in the clindamycin/tobramycin group) had received previous antimicrobial therapy. Of the patients evaluable for efficacy, 23 of 97 receiving meropenem and 13 of 94 receiving clindamycin/ tobramycin had received prior antimicrobial therapy.
APACHE II scores were obtained no more than 24 hours before surgery and treatment with one of the regimens was begun. Clinical and bacteriologic assessments were made before, during, and after treatment and after follow-up was completed Clinical laboratory evaluations, including assessments of renal and hepatic function, were carried out during treatment on days 2-4 and then weekly or as appropriate. Safety evaluations were performed daily during treatment, at the end of treatment, and after follow-up was completed. Patients, especially those who were considered cured on discharge from the hospital, often failed to return for late follow-up visits. This circumstance is not unusual for patients treated in urban, public hospitals, and in many of these instances, the patients' statuses were confirmed by telephone.
Treatment regimens. After enrollment in the trial, patients were assigned to trial treatment in a 1:1 ratio by a predetermined, computer-generated randomization schedule. The minimum duration of treatment was 5 days, although treatment could be classified as failure at the end of 48 hours. Patients could receive two doses of study medication before surgery; patients who did not receive two doses during the first 48 hours of treatment or two consecutive doses at any time were considered to be unevaluable for efficacy.
Patients received either meropenem (1,000 mg every 8 hours via a 20-to 30-minute intravenous infusion) or clindamycin phosphate (900 mg every 8 hours via a 20-minute intravenous infusion) and tobramycin sulfate (up to 5 mg/[kg • d] in three divided doses, administered in the same intravenous bag with the clindamycin). This aminoglycoside/lincosamide regimen was selected because it is still extensively used by surgeons for treatment of intra-abdominal infections.
To maintain the double-blind design, blood samples were drawn from all patients. Trial pharmacists, who were not blind to the trial assignments, adjusted the dose of tobramycin to provide peak serum levels of 5-10 mg/L and trough serum levels of <2 mg/L.
No other antibiotics except oral vancomycin (for diarrhea caused by Clostridium difficile) or oral nystatin (for oral candidiasis) could be administered concomitantly with the trial treatment. Other medications and blood products could be administered as needed. Only one major surgical procedure could be performed while the patient was in the trial. The need for other procedures led to withdrawal of the patient from the trial unless the second operation was performed to resolve persistent infection, in which case the trial treatment was declared a failure.
Adverse event reports were recorded promptly. Laboratory tests included routine blood and urine analyses as well as stool analysis for C. difficile toxin in patients with persistent diarrhea. Some tests were not performed at all centers.
Susceptibility of isolates. Bacterial infection was documented on the basis of the results of pretreatment cultures of blood, peritoneal fluid and other fluids, and infected intraabdominal fluid; these cultures were performed on the first day of trial treatment or u 3 days before entry into the trial if signs of continuing infection were present. Pathogens were isolated and identified. In vitro susceptibility testing was performed for each trial drug with use of the procedures and standards of the National Committee on Clinical Laboratory Standards. MIC and agar disk diffusion methods were permitted. It was required that at least one pathogen isolated before treatment show in vitro susceptibility or moderate-to-intermediate susceptibility to meropenem and clindamycin or tobramycin. These susceptibilities were defined as an MIC of ---.4 p,g/mL or a zone of inhibition of _.---14 mm for meropenem; an MIC of -.4.8 p,g/mL or a zone of inhibition of ,-15 mm for clindamycin; and an MIC of -...4 fi,g/mL or a zone of inhibition of ._. --13 mm for tobramycin. Cultures were performed during treatment and at the end of trial treatment if specimens were available.
Response to treatment. Both clinical and bacteriologic responses to the study treatments were rated by the investigator. Clinical responses were categorized as "cured" (no clinical signs and symptoms of infection), "improved" (significant abatement of signs and symptoms of infection), or "unchanged or worse." Both cured and improved outcomes were rated as "satisfactory," unchanged or worse was rated as "unsatisfactory." During follow-up, an unsatisfactory response after a previous satisfactory response was categorized as a relapse, while an unsatisfactory response at the end of treatment was categorized as unchanged or worse.
The bacteriologic response at the end of treatment was categorized as "success" (pretreatment pathogen[s] eradicated); "presumed success" (no specimens were obtained for culture, but the clinical response was satisfactory); "partial success" (some, but not all, organisms were eradicated, and there was a clinically satisfactory response in a patient with a polymicrobial infection); "failure" (the pretreatment pathogen was not eradicated at end of treatment); "presumed failure" (the signs and symptoms of infection worsened, but a culture could not be performed); "partial failure" (one, but not all, pretreatment pathogens were eradicated in a clinically unsatisfactory case); and "superinfection" (a new pathogen was isolated after the start of treatment). The first three categories were rated as a satisfactory response, while the last four were rated unsatisfactory. In cases in which no determination could be made, the investigator provided a reason for the lack of evaluation. During follow-up, the category relapse could also be used to rate bacteriologic response; relapse was rated as unsatisfactory.
Laboratory test results were evaluated for significant deviations from baseline and from normal ranges. Any changes considered to be related to the trial treatment were reported as drug-related adverse events. All adverse events were reported by the investigators, and the relationship of the adverse events to the study treatments (definitely related, probably related, possibly related, or not related) was recorded.
Statistical analyses. Demographic and clinical characteristics were summarized for both evaluable patients and all (intent-to-treat) patients. Criteria for exclusion from the efficacy evaluation are noted in table 2. Both treatments were expected to be reasonably successful, and the difference between the two treatments in terms of efficacy was not expected to be large. In such a study, an inordinately large sample size is required when conventional statistical parameters (a = 05; 1 -/3 = .08) are used. In this study, if the response rate was 90% for one treatment and 70% for the other treatment, then the power of a test of that difference would be only 0.65; if the difference between response rates was less, then the power would decrease. Therefore, the data to be analyzed were entered into 2 x 2 contingency tables and tested with use of the x2 method without Yates' correction (df = 1 x2 .' --3.84 indicated P --. .05) while the investigator was still blinded to screen for possible differences. If any x2 value exceeded 3.0 in this screening evaluation, the Mantel-Haenszel test was applied.
Analyses of the primary efficacy endpoints (clinical and bacteriologic response) were performed for evaluable patients and intent-to-treat patients at the end of treatment. The proportion of patients who demonstrated a satisfactory response was determined for each treatment group by approximation to the binomial distribution. Satisfactory response proportions for clinical and bacteriologic responses between treatment groups were compared with use of the Mantel-Haenszel X2 test. The P value from this test was reported with the appropriate confidence interval. Clinical and bacteriologic responses at both followup visits were also summarized.
All treated patients were included in the safety analysis. The incidence of all adverse events was summarized for each treatment group with use of terms preferred for the computerstored ambulatory record. The incidence of adverse events judged to be treatment-related was summarized separately. Between-group t tests were performed on mean changes between baseline and end-of-treatment laboratory values. The incidence of clinically defined laboratory changes was summarized.
Results
Demographic characteristics. A total of 427 patients, 215 of whom were randomized to treatment with meropenem and 212 of whom were randomized to treatment with clindamycin/ Mean ± SD total doses given 18.9 ± 7.1 19.5±6.1 6.1 * One patient randomized to this arm did not receive either treatment. t Includes appendicitis, not otherwise specified (meropenem group, 1 patient; clindamycin/tobramycin group, 1); gynecologic condition (meropenem, 1); hepatobiliary or pancreas (meropenem, 2; clindamycin/tobramycin, 4); peritonitis not otherwise specified (meropenem, 2; clindamycin/tobramycin, 3); upper gastrointestinal condition (meropenem, 1); and other not otherwise specified (meropenem, 3; clindamycin/tobramycin, 2). tobramycin, were entered from 13 centers; one patient (randomized to the meropenem arm) did not receive either trial treatment. A total of 191 patients (97 in the meropenem arm and 94 in the clindamycin/tobramycin arm) met all criteria for evaluation of efficacy, according to protocol criteria (table 2) .
Demographic and treatment data are summarized for all enrolled patients in table 3. The APACHE II scores were ...10 for 64% of all patients and -_.5 for 42%. The distribution of APACHE II scores was similar between the two treatment groups. The most frequent diagnosis was complicated appendicitis for both evaluable and nonevaluable patients (139 [72.8%] of 191 patients) (table 4). The infections treated in this study were caused by a variety of anaerobic organisms as well as by gram-positive and gram-negative aerobic pathogens.
The final clinical diagnoses for both evaluable and nonevaluable patients are listed in table 4. A total of 236 patients were found to be unevaluable for efficacy according to study protocol (table 5) . The most common reasons were an unacceptable clinical diagnosis usuallyacute appendicitis without perforation or abscess (47% of patients in the meropenem group and 42% in the clindamycin/tobramycin group) or failure to isolate a pretreatment pathogen (21% in the meropenem group and 27% in the clindamycin/tobramycin group).
Clinical outcome. The clinical response of all randomized, intent-to-treat, and evaluable patients was analyzed (table 6) . Efficacy data were available at the end of treatment for 132 patients in the meropenem group and 134 patients in the clindamycin/tobramycin group (table 6). Among patients meeting criteria for efficacy evaluation, 89 (92%) of 97 in the meropenem-treated group were rated as cured at the end of treatment, while 81 (86%) of 94 patients in the clindamycin/tobramycin group were rated as cured. An additional four patients in the meropenem group and six in the clindamycin/tobramycin group were rated as improved at the end of treatment, while only 4 and 7, respectively, were rated unchanged or worse. Similar results were seen at the follow-up evaluations. Clinical cure rates in this range are to be expected in a study in which the majority of patients have appendicitis.
Among all randomized (intent-to-treat) patients, 120 (91%) of 132 in the meropenem-treated group were rated as cured at the end of treatment, while 115 (86%) of 134 patients in the clindamycin/tobramycin group were rated as cured. An additional seven patients in the meropenem group and 11 in the clindamycin/tobramycin groups were rated as improved at the end of treatment; five and eight, respectively, were rated unchanged or worse. When clinical response was evaluated according to infection diagnosis, no significant differences were seen between treatment groups for the category of complicated appendicitis, which was the only diagnostic category large enough for a comparison.
Two patients (one in each treatment group) died during the course of the study. Both patients had gunshot wounds to the abdomen; the patient who received meropenem died of respiratory failure, and the patient who received clindamycin/tobramycin died of cardiac tamponade; neither death was attributed to treatment with the study drugs. At the end of treatment, four patients in the meropenem group and seven in the clindamycin/ tobramycin group were classified in the treatment failure category; no particular diagnosis seemed to be linked to treatment failure.
Bacteriologic outcome. In the intent-to-treat groups, bacteriologic success or presumed success was achieved at the end of treatment for 100 of 215 patients in the meropenem group and 95 of 212 patients in the clindamycin/ tobramycin group (table 7 ). An unsatisfactory bacteriologic response was observed for 5 of 215 patients in the meropenem group and 8 of 212 patients in the clindamycin/tobramycin group. Of the patients evaluable for efficacy, bacteriologic success or presumed success at the end of treatment was observed for 93 (96%) of 97 patients treated with meropenem and 87 (93%) of 94 patients treated with clindamycin/ tobramycin. Satisfactory bacteriologic responses were seen at the 4-14-day and 38-42-day follow-up visits for 61 (100%) of 61 and 17 (94%) of 18 evaluable patients, respectively, who received meropenem.
The responses of individual pathogens isolated in appropriate specimens (intra-abdominal specimens or blood) from evaluable patients are shown in table 8. Overall, both treatment regimens produced similar bacteriologic responses in terms of satisfactory clinical responses and treatment failures. Both meropenem and clindamycin/tobramycin were effective in the eradication of gram-negative and gram-positive aerobes and in the eradication of anaerobes isolated from intra-abdominal infections. Pathogens were identified at the individual study sites and were considered not to be contaminants by the investigators. Safety. All patients (i.e., 214 who received meropenem and 212 who received clindamycin/tobramycin) who received at least one dose of the study drugs were included in the safety evaluation. Of the patients who received meropenem, 88 (41%) experienced at least one adverse event; of the patients receiving clindamycin/tobramycin, 104 (49%) experienced at least one adverse event.
The most frequently reported adverse clinical events in both groups were diarrhea and nausea. Samples from four patients treated with meropenem and five treated with clindamycin/ tobramycin were assayed for C. difficile toxin; all nine assays were negative.
The abnormal treatment-related laboratory results most frequently reported were increased levels of aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, and lactate dehydrogenase. These abnormalities plus rash and thrombocythemia were reported at approximately the same frequencies for patients in the clindamycin/tobramycin group.
At least one adverse event considered by the investigator to be drug related was reported for 45 (21%) of the patients who received meropenem and 58 (27%) of the patients who received clindamycin/tobramycin. The most frequently reported drugrelated clinical adverse event in both groups was diarrhea, which was reported for 7 (3.3%) of patients who received meropenem and 10 (4.7%) who received clindamycin/tobramycin. Drug-related adverse events that occurred in two or more patients are summarized in table 9. There were no reports of seizures in either group.
Four patients treated with clindamycin/tobramycin were withdrawn from the trial because of adverse events, all of which were judged to be drug related by the investigator; no patients in the meropenem group were withdrawn because of adverse events. The first patient was withdrawn after a moderate increase in the serum tobramycin level and creatinine level were detected; the second patient was withdrawn because a rash developed; the third was withdrawn after an episode of mild hiccups and dizziness; and the fourth was withdrawn after severe kidney failure and severe sepsis developed.
The two patients (one in the meropenem group and one in the clindamycin/tobramycin group) who died during the course of the study both had infectious complications of gunshot wounds to the abdomen; neither case was assessed by the investigators to be related to treatment.
Discussion
Monotherapy with meropenem resulted in high rates (96%) of satisfactory clinical and bacteriologic responses at the end of treatment in this double-blind trial; these rates were comparable to those observed with the clindamycin/tobramycin regimen. Satisfactory eradication rates for pathogens isolated before treatment were also similar overall between the treatment groups. In other studies, meropenem has been found to be Table 7 . Bacteriologic results of therapy for intra-abdominal infections with meropenem or clindamycin/tobramycin among evaluable and intent-to-treat patients. equally as effective as imipenem/cilastatin for the treatment of intra-abdominal infections and skin and soft-tissue infections [12] [13] [14] [15] [16] . The potential advantages of meropenem monotherapy vs. therapy with other regimens for intra-abdominal infections are that drug-level determinations are not required, the risk of drug toxicity is reduced, and the dosing schedule is simplified, which may contribute to overall cost savings. In evaluating the safety data from this trial, it should be noted that most of the patients had normal renal function: pretreatment creatinine clearance was -_51 mL/min for only 15 patients. Most of the patients entered in the trial had low APACHE II scores. However, all patients had at least one clinically significant underlying condition, for which 99% received concomitant nonantimicrobial drugs during the trial. At the time of entry into the study, -22% of patients were judged to be in fair condition or poor general condition. It is not possible to draw any firm conclusions about the comparative safety of the trial drugs in older patients because only 4% of the patients enrolled in this trial were __--.65 years of age.
The results of several clinical investigations have suggested that the safety profile of meropenem compares favorably with that of imipenem/cilastatin [2, [12] [13] [14] [15] [16] [17] [18] [19] [20] . In a review of safety data on 3,220 patient exposures to meropenem vs. 2,960 patient exposures to a variety of other agents (including cephalosporins given alone or in combination with other drugs and imipenem/cilastatin), it was reported that the overall pattern and frequency of adverse events associated with meropenem were similar to those associated with the other f3-lactam agents [21] .
The most frequently reported clinical adverse events related to meropenem therapy were diarrhea, nausea and vomiting, rash, and pruritus; all of these adverse events occurred with similar frequency among the patients receiving the other agents. The most frequent laboratory abnormalities were thrombocytosis, eosinophilia, and changes in hepatic biochemical parameters; there were no significant differences between meropenem and the comparator agents in terms of the frequency of these events [21] . Meropenem penetrates tissues extensively, which may be a clinical asset. In a recent report, a single intravenous 1,000-mg dose yielded concentrations of meropenem in the colon, omentum, stomach, and fascia as well as in bile and peritoneal fluid that were sufficient to inhibit the growth of common intraabdominal pathogens [11] . In an earlier study, rapid penetration of meropenem into peritoneal fluid was demonstrated in 24 randomly selected patients undergoing gastrointestinal surgery [7] . Two hours after a single intravenous dose, mean peritoneal penetration was 95% of the corresponding area under the curve of the drug's concentration in plasma.
Similarly, in a human distribution study, meropenem rapidly penetrated experimentally induced inflammatory exudates [8] . The mean peak concentration of meropenem in the exudates occurred between 0.5 hours and 1.0 hours after intravenous administration, with a corresponding mean exudate-to-serum penetration ratio of 110.7%. An assessment of the pharmacokinetics of meropenem in patients with intra-abdominal infections requiring surgery indicates that a dose of 1,000 mg given every 8 hours was adequate for therapeutic coverage of susceptible organisms [10] .
Meropenem may be given either by intravenous infusion or bolus injection without associated nausea and vomiting [22] . The occurrence of drug-related nausea and/or vomiting with imipenem may be related to both the dose and the speed of 
Conclusions
This double-blind, randomized trial has demonstrated the efficacy of meropenem (1,000 mg given iv every 8 hours) as antibacterial monotherapy for bacterial intra-abdominal infections (the majority of which were complicated appendicitis) requiring surgery and parenteral antibiotic treatment. The clinical and bacterial response rates were similar to those for a combination regimen of clindamycin (900 mg given iv every Table 9 . Drug-related adverse events that occurred in two or more patients in a randomized, multicenter trial of meropenem vs. clindamycin/tobramycin for treatment of intra-abdominal infections. . In addition to being effective, meropenem appeared to be well tolerated and safe. Both the type and frequency of adverse events reported for the meropenem-treated patients were similar to those reported for the patients treated with clindamycin/tobramycin.
